These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Vogl TJ; Kümmel S; Hammerstingl R; Schellenbeck M; Schumacher G; Balzer T; Schwarz W; Müller PK; Bechstein WO; Mack MG; Söllner O; Felix R Radiology; 1996 Jul; 200(1):59-67. PubMed ID: 8657946 [TBL] [Abstract][Full Text] [Related]
3. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Hamm B; Staks T; Mühler A; Bollow M; Taupitz M; Frenzel T; Wolf KJ; Weinmann HJ; Lange L Radiology; 1995 Jun; 195(3):785-92. PubMed ID: 7754011 [TBL] [Abstract][Full Text] [Related]
4. Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg). Giovagnoni A; Paci E Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):61-72. PubMed ID: 8673717 [TBL] [Abstract][Full Text] [Related]
5. Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats. Clément O; Mühler A; Vexler V; Berthezène Y; Brasch RC Invest Radiol; 1992 Aug; 27(8):612-9. PubMed ID: 1428739 [TBL] [Abstract][Full Text] [Related]
6. Hepatobiliary enhancement with Gd-EOB-DTPA: comparison of spin-echo and STIR imaging for detection of experimental liver metastases. Mühler A; Clément O; Vexler V; Berthezène Y; Rosenau W; Brasch RC Radiology; 1992 Jul; 184(1):207-13. PubMed ID: 1609081 [TBL] [Abstract][Full Text] [Related]
7. Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging. Reimer P; Rummeny EJ; Daldrup HE; Hesse T; Balzer T; Tombach B; Peters PE Eur Radiol; 1997; 7(2):275-80. PubMed ID: 9038130 [TBL] [Abstract][Full Text] [Related]
8. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects. Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513 [TBL] [Abstract][Full Text] [Related]
10. [Oral contrast media for magnetic resonance tomography of the abdomen. III. Initial patient research with gadolinium-DTPA]. Claussen C; Kornmesser W; Laniado M; Kaminsky S; Hamm B; Felix R Rofo; 1988 Jun; 148(6):683-9. PubMed ID: 2837806 [TBL] [Abstract][Full Text] [Related]
11. [The dynamic magnetic resonance study of focal liver lesions by FLASH sequences with bolus intravenous gadolinium-DTPA]. Olivetti L; Grazioli L; Maroldi R; Matricardi L; Milanesio L Radiol Med; 1992 Apr; 83(4):353-60. PubMed ID: 1318558 [TBL] [Abstract][Full Text] [Related]
12. [Oral contrast media for the magnetic resonance tomography of the abdomen. A clinical trial of the tolerance for gadolinium-DTPA]. Kaminsky S; Laniado M; Gogoll M; Kornmesser W; Clauss W; Felix R Rofo; 1992 Jan; 156(1):17-23. PubMed ID: 1733470 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment. Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212 [TBL] [Abstract][Full Text] [Related]
14. Diffusion weighted imaging of liver lesions suspect for metastases: Apparent diffusion coefficient (ADC) values and lesion contrast are independent from Gd-EOB-DTPA administration. Benndorf M; Schelhorn J; Dietzel M; Kaiser WA; Baltzer PA Eur J Radiol; 2012 Aug; 81(8):e849-53. PubMed ID: 22575171 [TBL] [Abstract][Full Text] [Related]
20. T2-weighted magnetic resonance imaging of the liver: evaluation of the effect in signal intensity after Gd-EOB-DTPA enhancement. Tamada T; Ito K; Yoshida K; Sone T; Murakami K; Kanki A; Watanabe S; Higashi H; Yamashita T J Comput Assist Tomogr; 2010; 34(2):182-6. PubMed ID: 20351500 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]